Skip to main content
Premium Trial:

Request an Annual Quote

10x Genomics Acquires Epinomics

NEW YORK (GenomeWeb) – 10x Genomics said on Tuesday that it has acquired Epinomics, a startup that spun out of Stanford University to commercialize technology for mapping chromatin regions across the genome.

Epinomics has been developing its technology for clinical applications, including using epigenomic signatures to predict response to immunotherapy. It has a collaboration with Stanford's Park Institute for Cancer Immunotherapy to use biomarkers and epigenomics technology to improve cancer immunotherapies.

Privately held 10x Genomics plans to integrate Epinomics' ATAC-seq epigenetic technology onto its Chromium system and plans to launch a single-cell ATAC solution by the end of the year.

"Today's acquisition gives us a strong team, IP, and technology that has been enthusiastically validated by customers," 10x Genomics CEO Serge Saxonov said in a statement. "It provides a foundation for powerful new products and positions us well to become the leader in epigenomics."

Financial terms of the acquisition were not disclosed. Epinomics is backed by venture firms including Lightspeed Venture Partners, Felicis Ventures, and Founders Fund.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.